These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38528628)

  • 1. Co-designing strategies to implement long-acting injectable PrEP for sexual minority men in Chicago: a study protocol for an innovation tournament and implementation mapping.
    Van Pelt AE; Casline E; Phillips G; Cestou J; Mustanski B; Cook G; Beidas RS
    Implement Sci Commun; 2024 Mar; 5(1):29. PubMed ID: 38528628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC).
    Warren M; Nyagah W; Verde Hashim C; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26094. PubMed ID: 37439050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing output from two methods of participatory design for developing implementation strategies: traditional contextual inquiry vs. rapid crowd sourcing.
    Becker-Haimes EM; Ramesh B; Buck JE; Nuske HJ; Zentgraf KA; Stewart RE; Buttenheim A; Mandell DS
    Implement Sci; 2022 Jul; 17(1):46. PubMed ID: 35854367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.
    Lorenzetti L; Dinh N; van der Straten A; Fonner V; Ridgeway K; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26107. PubMed ID: 37439057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.
    Fonner VA; Ridgeway K; van der Straten A; Lorenzetti L; Dinh N; Rodolph M; Schaefer R; Schmidt HA; Nguyen VTT; Radebe M; Peralta H; Baggaley R
    AIDS; 2023 May; 37(6):957-966. PubMed ID: 36723489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinician crowdsourcing challenge: using participatory design to seed implementation strategies.
    Stewart RE; Williams N; Byeon YV; Buttenheim A; Sridharan S; Zentgraf K; Jones DT; Hoskins K; Candon M; Beidas RS
    Implement Sci; 2019 Jun; 14(1):63. PubMed ID: 31200730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
    Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
    Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
    Durham SH; Milam A; Waer D; Chahine EB
    Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.
    Mitchell KM; Boily MC; Hanscom B; Moore M; Todd J; Paz-Bailey G; Wejnert C; Liu A; Donnell DJ; Grinsztejn B; Landovitz RJ; Dimitrov DT
    Lancet Reg Health Am; 2023 Feb; 18():100416. PubMed ID: 36844011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon G; Ghosn J
    HIV Med; 2023 Jun; 24(6):653-663. PubMed ID: 36468218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design.
    Farooq HZ; Apea V; Kasadha B; Ullah S; Hilton-Smith G; Haley A; Scherzer J; Hand J; Paparini S; Phillips R; Orkin CM
    BMJ Open; 2023 Jul; 13(7):e070666. PubMed ID: 37423623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
    Stansfield SE; Heitner J; Mitchell KM; Doyle CM; Milwid RM; Moore M; Donnell DJ; Hanscom B; Xia Y; Maheu-Giroux M; Vijver DV; Wang H; Barnabas R; Boily MC; Dimitrov DT
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26109. PubMed ID: 37439080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).
    Rael CT; Lopez-Ríos J; McKenna SA; Das D; Dolezal C; Abascal E; Carballo-Diéguez A; Schnall R; Hope TJ; Bauermeister J; Bockting W
    AIDS Behav; 2021 Dec; 25(12):4180-4192. PubMed ID: 34216284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting injectable cabotegravir for the prevention of HIV infection.
    Clement ME; Kofron R; Landovitz RJ
    Curr Opin HIV AIDS; 2020 Jan; 15(1):19-26. PubMed ID: 31644481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
    Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV Prevention and Care Among Black Cisgender Sexual Minority Men and Transgender Women: Protocol for an HIV Status-Neutral Cohort Study Using an Observational-Implementation Hybrid Approach.
    Knox JR; Dolotina B; Moline T; Matthews I; Durrell M; Hanson H; Almirol E; Hotton A; Pagkas-Bather J; Chen YT; English D; Manuzak J; Rower JE; Miles C; Millar B; Jean-Louis G; Rendina HJ; Martins SS; Grov C; Hasin DS; Carrico AW; Shoptaw S; Schneider JA; Duncan DT
    JMIR Res Protoc; 2023 Dec; 12():e48548. PubMed ID: 38039075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.